Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 4/2019

01-07-2019 | Obesity | Review

Impact of bariatric surgery on type 2 diabetes: contribution of inflammation and gut microbiome?

Authors: Jean Debédat, Chloé Amouyal, Judith Aron-Wisnewsky, Karine Clément

Published in: Seminars in Immunopathology | Issue 4/2019

Login to get access

Abstract

Obesity is a chronic low-grade inflammatory disease (both at the systemic and adipose tissue level) that continues to rise worldwide. It is associated with an abundance of comorbidities, including type 2 diabetes (T2D). Bariatric surgery, which induces modifications of the intestinal tract, is to date the most successful treatment for obesity. Its use has dramatically increased in number as it enables both weight reduction and metabolic improvements, with 60% of patients even achieving diabetes remission. Several mechanisms are actually demonstrated to be involved in those clinical improvements. Importantly, both obesity and T2D share many phenotypic characteristics, including increased systemic and adipose tissue inflammation, as well as gut microbiota dysbiosis. These characteristics are deeply modulated after bariatric surgery. This review will address the host metabolic changes observed after bariatric surgery, focusing on the induced gut architectural changes, as well as on the modifications of the inflammatory tone and the gut microbiota.
Literature
1.
2.
Tordjman J et al (2009) Association between omental adipose tissue macrophages and liver histopathology in morbid obesity: influence of glycemic status. J Hepatol 51:354–362CrossRefPubMed
3.
Skurk T, Alberti-Huber C, Herder C, Hauner H (2007) Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 92:1023–1033CrossRefPubMed
4.
5.
Cancello R et al (2006) Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 55:1554–1561CrossRefPubMed
6.
Harman-Boehm I et al (2007) Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. J Clin Endocrinol Metab 92:2240–2247CrossRefPubMed
7.
Dalmas E, Clément K, Guerre-Millo M (2011) Defining macrophage phenotype and function in adipose tissue. Trends Immunol 32:307–314CrossRefPubMed
8.
Aron-Wisnewsky J et al (2009) Human adipose tissue macrophages: m1 and m2 cell surface markers in subcutaneous and omental depots and after weight loss. J Clin Endocrinol Metab 94:4619–4623CrossRefPubMed
9.
10.
Huber J et al (2008) CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity. J Clin Endocrinol Metab 93:3215–3221CrossRefPubMed
11.
Wentworth JM et al (2010) Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. Diabetes 59:1648–1656CrossRefPubMedPubMedCentral
12.
Pasarica M et al (2009) Lower total adipocyte number but no evidence for small adipocyte depletion in patients with type 2 diabetes. Diabetes Care 32:900–902CrossRefPubMedPubMedCentral
13.
14.
Stienstra R et al (2011) Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci U S A 108:15324–15329CrossRefPubMedPubMedCentral
15.
Dalmas E et al (2014) T cell-derived IL-22 amplifies IL-1β-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes. Diabetes 63:1966–1977CrossRefPubMed
16.
Divoux A et al (2012) Mast cells in human adipose tissue: link with morbid obesity, inflammatory status, and diabetes. J Clin Endocrinol Metab 97:E1677–E1685CrossRefPubMed
17.
Rouault C et al (2013) Roles of chemokine ligand-2 (CXCL2) and neutrophils in influencing endothelial cell function and inflammation of human adipose tissue. Endocrinology 154:1069–1079CrossRefPubMed
18.
Viardot A et al (2012) Obesity is associated with activated and insulin resistant immune cells. Diabetes Metab Res Rev 28:447–454CrossRefPubMed
19.
Nishimura S et al (2009) CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med:914–915, 920
20.
Sell H, Habich C, Eckel J (2012) Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol 8:709–716CrossRefPubMed
21.
22.
Ridaura VK et al (2013) Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341:1241214CrossRefPubMed
23.
Bohan R et al (2018) Gut microbiota: a potential manipulator for host adipose tissue and energy metabolism. J Nutr Biochem 64:206–217CrossRefPubMed
24.
Cotillard A et al (2013) Dietary intervention impact on gut microbial gene richness. Nature 500:585–588CrossRefPubMed
25.
Le Chatelier E et al (2013) Richness of human gut microbiome correlates with metabolic markers. Nature 500:541–546CrossRefPubMed
26.
27.
Cani PD et al (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56:1761–1772CrossRefPubMed
28.
Cani PD et al (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58:1091–1103CrossRefPubMed
29.
Cani PD et al (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57:1470–1481CrossRefPubMed
30.
31.
Dyson PA (2010) The therapeutics of lifestyle management on obesity. Diabetes Obes Metab 12:941–946CrossRefPubMed
32.
33.
Sturm R, Hattori A (2013) Morbid obesity rates continue to rise rapidly in the United States. Int J Obes. 2005 37:889–891
34.
35.
Fried M et al (2014) Interdisciplinary European guidelines on metabolic and bariatric surgery. Obes Surg 24:42–55CrossRefPubMed
36.
Rubino F et al (2016) Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 39:861–877CrossRefPubMed
37.
Dixon JB, Straznicky NE, Lambert EA, Schlaich MP, Lambert GW (2011) Surgical approaches to the treatment of obesity. Nat Rev Gastroenterol Hepatol 8:429–437CrossRefPubMed
38.
Zellmer JD, Mathiason MA, Kallies KJ, Kothari SN (2014) Is laparoscopic sleeve gastrectomy a lower risk bariatric procedure compared with laparoscopic Roux-en-Y gastric bypass? A meta-analysis. Am J Surg 208:903–910; discussion 909–910CrossRefPubMed
39.
Osland E, Yunus RM, Khan S, Memon B, Memon MA (2017) Weight loss outcomes in laparoscopic vertical sleeve gastrectomy (LVSG) versus laparoscopic Roux-en-Y gastric bypass (LRYGB) procedures: a meta-analysis and systematic review of randomized controlled trials. Surg Laparosc Endosc Percutan Tech 27:8–18PubMed
40.
Sjöström L et al (2012) Bariatric surgery and long-term cardiovascular events. JAMA J Am Med Assoc 307:56–65CrossRef
41.
42.
43.
44.
Schauer PR, Mingrone G, Ikramuddin S, Wolfe B (2016) Clinical outcomes of metabolic surgery: efficacy of glycemic control, weight loss, and remission of diabetes. Diabetes Care 39:902–911CrossRefPubMedPubMedCentral
45.
46.
Pournaras DJ et al (2012) Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. Br J Surg 99:100–103CrossRefPubMed
47.
48.
49.
Mingrone G et al (2012) Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366:1577–1585CrossRefPubMed
50.
Thereaux J et al (2017) Long-term follow-up after bariatric surgery in a national cohort. Br J Surg 104:1362–1371CrossRefPubMed
51.
Mingrone G et al (2015) Bariatric–metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 386:964–973CrossRefPubMed
52.
Courcoulas AP et al (2015) Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment: a randomized clinical trial. JAMA Surg 150:931–940CrossRefPubMedPubMedCentral
53.
Brethauer SA et al (2013) Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg 258:628–636; discussion 636–637CrossRefPubMed
54.
Aminian A, Brethauer SA, Kashyap SR, Kirwan JP, Schauer PR (2014) DiaRem score: external validation. Lancet Diabetes Endocrinol 2:12–13CrossRefPubMed
55.
Mehaffey JH et al (2017) Type 2 diabetes remission following gastric bypass: does diarem stand the test of time? Surg Endosc 31:538–542CrossRefPubMed
56.
Still CD et al (2014) Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study. Lancet Diabetes Endocrinol 2:38–45CrossRefPubMedPubMedCentral
57.
Lee W-J et al (2013) Predicting success of metabolic surgery: age, body mass index, C-peptide, and duration score. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 9:379–384CrossRef
58.
59.
Pucci A et al (2018) Type 2 diabetes remission 2 years post Roux-en-Y gastric bypass and sleeve gastrectomy: the role of the weight loss and comparison of DiaRem and DiaBetter scores. Diabet Med J Br Diabet Assoc 35:360–367CrossRef
60.
Cotillard A et al (2015) Type 2 diabetes remission after gastric bypass: what is the best prediction tool for clinicians? Obes Surg 25:1128–1132CrossRefPubMed
61.
Lee MH et al (2015) Predictors of long-term diabetes remission after metabolic surgery. J Gastrointest Surg Off J Soc Surg Aliment Tract 19:1015–1021CrossRef
62.
Wood GC, Mirshahi T, Still CD, Hirsch AG (2016) Association of DiaRem score with cure of type 2 diabetes following bariatric surgery. JAMA Surg 151:779–781CrossRefPubMedPubMedCentral
63.
Dicker D, Yahalom R, Comaneshter DS, Vinker S (2016) Long-term outcomes of three types of bariatric surgery on obesity and type 2 diabetes control and remission. Obes Surg 26:1814–1820CrossRefPubMed
64.
Ashrafian H et al (2011) Diabetes resolution and hyperinsulinaemia after metabolic Roux-en-Y gastric bypass. Obes Rev Off J Int Assoc Study Obes 12:e257–e272CrossRef
65.
Pories WJ et al (1995) Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222:339–350; discussion 350–352CrossRefPubMedPubMedCentral
66.
Laurenius A et al (2012) Changes in eating behaviour and meal pattern following Roux-en-Y gastric bypass. Int J Obes. 2005 36:348–355
67.
68.
Aron-Wisnewsky J et al (2016) Nutritional and protein deficiencies in the short term following both gastric bypass and gastric banding. PLoS One 11:e0149588CrossRefPubMedPubMedCentral
69.
Gras-Miralles B et al (2014) Caloric intake capacity as measured by a standard nutrient drink test helps to predict weight loss after bariatric surgery. Obes Surg 24:2138–2144CrossRefPubMed
70.
le Roux CW et al (2006) Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243:108–114CrossRefPubMedPubMedCentral
71.
Lips MA et al (2014) Calorie restriction is a major determinant of the short-term metabolic effects of gastric bypass surgery in obese type 2 diabetic patients. Clin Endocrinol 80:834–842CrossRef
72.
Steinert RE et al (2017) Ghrelin, CCK, GLP-1, and PYY(3-36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol Rev 97:411–463CrossRefPubMed
73.
Yousseif A et al (2014) Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans. Obes Surg 24:241–252CrossRefPubMed
74.
Laferrère B et al (2008) Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 93:2479–2485CrossRefPubMedPubMedCentral
75.
Laferrère B et al (2010) Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes. J Clin Endocrinol Metab 95:4072–4076CrossRefPubMedPubMedCentral
76.
Cummings DE et al (2002) Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346:1623–1630CrossRefPubMed
77.
Holter MM et al (2017) Glucose metabolism after gastric banding and gastric bypass in individuals with type 2 diabetes: weight loss effect. Diabetes Care 40:7–15CrossRefPubMed
78.
79.
80.
Laferrère B, Pattou F (2018) Weight-independent mechanisms of glucose control after Roux-en-Y gastric bypass. Front Endocrinol 9
81.
Castagneto Gissey L, Casella Mariolo J, Mingrone G (2018) Intestinal peptide changes after bariatric and minimally invasive surgery: relation to diabetes remission. Peptides 100:114–122CrossRefPubMed
82.
83.
Stano S et al (2017) Effect of meal size and texture on gastric pouch emptying and glucagon-like peptide 1 after gastric bypass surgery. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 13:1975–1983CrossRef
84.
Jacobsen SH et al (2013) Effects of gastric bypass surgery on glucose absorption and metabolism during a mixed meal in glucose-tolerant individuals. Diabetologia 56:2250–2254CrossRefPubMed
85.
Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ (2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609–613CrossRefPubMed
86.
Knop FK et al (2007) Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 56:1951–1959CrossRefPubMed
87.
Xu G, Stoffers DA, Habener JF, Bonner-Weir S (1999) Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270–2276CrossRefPubMed
88.
Vetter ML et al (2015) GLP-1 plays a limited role in improved glycemia shortly after Roux-en-Y gastric bypass: a comparison with intensive lifestyle modification. Diabetes 64:434–446CrossRefPubMed
89.
90.
Mokadem M, Zechner JF, Margolskee RF, Drucker DJ, Aguirre V (2014) Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency. Mol Metab 3:191–201CrossRefPubMed
91.
Wilson-Pérez HE et al (2013) Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency. Diabetes 62:2380–2385CrossRefPubMedPubMedCentral
92.
Garibay D et al (2016) β-Cell glucagon-like peptide-1 receptor contributes to improved glucose tolerance after vertical sleeve gastrectomy. Endocrinology 157:3405–3409CrossRefPubMedPubMedCentral
93.
94.
Marchetti P et al (2012) A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia 55:3262–3272CrossRefPubMed
95.
96.
Service GJ et al (2005) Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 353:249–254CrossRefPubMed
97.
Dadheech N, Garrel D, Buteau J (2018) Evidence of unrestrained beta-cell proliferation and neogenesis in a patient with hyperinsulinemic hypoglycemia after gastric bypass surgery. Islets 10:213–220CrossRefPubMedPubMedCentral
98.
Meier JJ, Butler AE, Galasso R, Butler PC (2006) Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased-cell turnover. Diabetes Care 29:1554–1559CrossRefPubMed
99.
Lautenbach A et al (2018) Adaptive changes in pancreas post Roux-en-Y gastric bypass induced weight loss. Diabetes Metab Res Rev 34:e3025CrossRefPubMed
100.
Gaborit B et al (2015) Ectopic fat storage in the pancreas using 1H-MRS: importance of diabetic status and modulation with bariatric surgery-induced weight loss. Int J Obes 2005(39):480–487CrossRef
101.
Zhou X, Qian B, Ji N, Lui C, Liu Z, Li B, Zhou H, Yan C (2016) Pancreatic hyperplasia after gastric bypass surgery in a GK rat model of non-obese type 2 diabetes. J Endocrinol 228:13–23CrossRefPubMed
102.
Zhang S, Guo W, Wu J, Gong L, Li Q, Xiao X, Zhang J, Wang Z (2017) Increased β-cell mass in obese rats after gastric bypass: a potential mechanism for improving glycemic control. Med Sci Monit 23:2151–2158CrossRefPubMedPubMedCentral
103.
McGavigan AK, Garibay D, Henseler ZM, Chen J, Bettaieb A, Haj FG, Ley RE, Chouinard ML, Cummings BP (2017) TGR5 contributes to glucoregulatory improvements after vertical sleeve gastrectomy in mice. Gut 66:226–234CrossRefPubMed
104.
Cummings BP, Bettaieb A, Graham JL, Kim J, Ma F, Shibata N, Stanhope KL, Giulivi C, Hansen F, Jelsing J, Vrang N, Kowala M, Chouinard ML, Haj FG, Havel PJ (2013) Bile-acid-mediated decrease in endoplasmic reticulum stress: a potential contributor to the metabolic benefits of ileal interposition surgery in UCD-T2DM rats. Dis Model Mech 6:443–456CrossRefPubMed
105.
Dutia R, Brakoniecki K, Bunker P, Paultre F, Homel P, Carpentier AC, McGinty J, Laferrere B (2014) Limited recovery of β-cell function after gastric bypass despite clinical diabetes remission. Diabetes 63:1214–1223CrossRefPubMedPubMedCentral
106.
Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, DeForest L, Cooper S, Brubaker PL (1997) Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol 15:673–677CrossRefPubMed
107.
Drucker DJ, Erlich P, Asa SL, Brubaker PL (1996) Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A 93:7911–7916CrossRefPubMedPubMedCentral
108.
le Roux CW, Borg C, Wallis K, Vincent RP, Bueter M, Goodlad R, Ghatei MA, Patel A, Bloom SR, Aylwin SJB (2010) Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferation. Ann Surg 252:50–56CrossRefPubMed
109.
Cazzo E, Pareja JC, Chaim EA, Geloneze B, Barreto MRL, Magro DO (2017) GLP-1 and GLP-2 levels are correlated with satiety regulation after Roux-en-Y gastric bypass: results of an exploratory prospective study. Obes Surg 27:703–708CrossRefPubMed
110.
Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS, Tofteng F, Poulsen SS, Madsen JL, Holst JJ, Mortensen PB (2001) Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 120:806–815CrossRefPubMed
111.
Iqbal CW, Qandeel HG, Zheng Y, Duenes JA, Sarr MG (2008) Mechanisms of ileal adaptation for glucose absorption after proximal-based small bowel resection. J Gastrointest Surg Off J Soc Surg Aliment Tract 12:1854–1864; discussion 1864–1865CrossRef
112.
Li B, Lu Y, Srikant CB, Gao Z-H, Liu J-L (2013) Intestinal adaptation and Reg gene expression induced by antidiabetic duodenal-jejunal bypass surgery in Zucker fatty rats. Am J Physiol Gastrointest Liver Physiol 304:G635–G645CrossRefPubMed
113.
Taqi E, Wallace LE, de Heuvel E, Chelikani PK, Zheng H, Berthoud HR, Holst JJ, Sigalet DL (2010) The influence of nutrients, biliary-pancreatic secretions, and systemic trophic hormones on intestinal adaptation in a Roux-en-Y bypass model. J Pediatr Surg 45:987–995CrossRefPubMed
114.
Cavin J-B, Voitellier E, Cluzeaud F, Kapel N, Marmuse JP, Chevallier JM, Msika S, Bado A, le Gall M (2016) Malabsorption and intestinal adaptation after one anastomosis gastric bypass compared with Roux-en-Y gastric bypass in rats. Am J Physiol-Gastrointest Liver Physiol 311:G492–G500CrossRefPubMed
115.
Cavin J-B et al (2016) Differences in alimentary glucose absorption and intestinal disposal of blood glucose after Roux-en-Y gastric bypass vs sleeve gastrectomy. Gastroenterology 150:454–464.e9CrossRefPubMed
116.
Troy S, Soty M, Ribeiro L, Laval L, Migrenne S, Fioramonti X, Pillot B, Fauveau V, Aubert R, Viollet B, Foretz M, Leclerc J, Duchampt A, Zitoun C, Thorens B, Magnan C, Mithieux G, Andreelli F (2008) Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice. Cell Metab 8:201–211CrossRefPubMed
117.
Saeidi N, Meoli L, Nestoridi E, Gupta NK, Kvas S, Kucharczyk J, Bonab AA, Fischman AJ, Yarmush ML, Stylopoulos N (2013) Reprogramming of intestinal glucose metabolism and glycemic control in rats after gastric bypass. Science 341:406–410CrossRefPubMedPubMedCentral
118.
Baud G, Daoudi M, Hubert T, Raverdy V, Pigeyre M, Hervieux E, Devienne M, Ghunaim M, Bonner C, Quenon A, Pigny P, Klein A, Kerr-Conte J, Gmyr V, Caiazzo R, Pattou F (2016) Bile diversion in Roux-en-Y gastric bypass modulates sodium-dependent glucose intestinal uptake. Cell Metab 23:547–553CrossRefPubMed
119.
Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K (2009) TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10:167–177CrossRefPubMedPubMedCentral
120.
Kohli R, Bradley D, Setchell KD, Eagon JC, Abumrad N, Klein S (2013) Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab 98:E708–E712CrossRefPubMedPubMedCentral
121.
Patti M-E, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, Badman MK, Maratos-Flier E, Mun EC, Pihlajamaki J, Auwerx J, Goldfine AB (2009) Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obes Silver Spring Md 17:1671–1677CrossRef
122.
Ryan KK, Tremaroli V, Clemmensen C, Kovatcheva-Datchary P, Myronovych A, Karns R, Wilson-Pérez HE, Sandoval DA, Kohli R, Bäckhed F, Seeley RJ (2014) FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509:183–188CrossRefPubMedPubMedCentral
123.
Albaugh VL, Flynn CR, Cai S, Xiao Y, Tamboli RA, Abumrad NN (2015) Early increases in bile acids post Roux-en-Y gastric bypass are driven by insulin-sensitizing, secondary bile acids. J Clin Endocrinol Metab 100:E1225–E1233CrossRefPubMedPubMedCentral
124.
125.
Wu T, Bound MJ, Standfield SD, Jones KL, Horowitz M, Rayner CK (2013) Effects of taurocholic acid on glycemic, glucagon-like peptide-1, and insulin responses to small intestinal glucose infusion in healthy humans. J Clin Endocrinol Metab 98:E718–E722CrossRefPubMed
126.
Li F, Jiang C, Krausz KW, Li Y, Albert I, Hao H, Fabre KM, Mitchell JB, Patterson AD, Gonzalez FJ (2013) Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun 4:2384CrossRefPubMed
127.
128.
Fang S, Suh JM, Reilly SM, Yu E, Osborn O, Lackey D, Yoshihara E, Perino A, Jacinto S, Lukasheva Y, Atkins AR, Khvat A, Schnabl B, Yu RT, Brenner DA, Coulter S, Liddle C, Schoonjans K, Olefsky JM, Saltiel AR, Downes M, Evans RM (2015) Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 21:159–165CrossRefPubMedPubMedCentral
129.
Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall HU, Bamberg K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F (2013) Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 17:225–235CrossRefPubMed
130.
Furet J-P, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, Mariat D, Corthier G, Dore J, Henegar C, Rizkalla S, Clement K (2010) Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss. Diabetes 59:3049–3057CrossRefPubMedPubMedCentral
131.
Kong L-C, Tap J, Aron-Wisnewsky J, Pelloux V, Basdevant A, Bouillot JL, Zucker JD, Doré J, Clément K (2013) Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. Am J Clin Nutr 98:16–24CrossRefPubMed
132.
133.
Graessler J, Qin Y, Zhong H, Zhang J, Licinio J, Wong ML, Xu A, Chavakis T, Bornstein AB, Ehrhart-Bornstein M, Lamounier-Zepter V, Lohmann T, Wolf T, Bornstein SR (2013) Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharm J 13:514–522
134.
Tremaroli V, Karlsson F, Werling M, Ståhlman M, Kovatcheva-Datchary P, Olbers T, Fändriks L, le Roux CW, Nielsen J, Bäckhed F (2015) Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metab 22:228–238CrossRefPubMedPubMedCentral
135.
Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y, Parameswaran P, Crowell MD, Wing R, Rittmann BE, Krajmalnik-Brown R (2009) Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A 106:2365–2370CrossRefPubMedPubMedCentral
136.
Aron-Wisnewsky J, Doré J, Clement K (2012) The importance of the gut microbiota after bariatric surgery. Nat Rev Gastroenterol Hepatol 9:590–598CrossRefPubMed
137.
Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, Costea PI, Godneva A, Kalka IN, Bar N, Shilo S, Lador D, Vila AV, Zmora N, Pevsner-Fischer M, Israeli D, Kosower N, Malka G, Wolf BC, Avnit-Sagi T, Lotan-Pompan M, Weinberger A, Halpern Z, Carmi S, Fu J, Wijmenga C, Zhernakova A, Elinav E, Segal E (2018) Environment dominates over host genetics in shaping human gut microbiota. Nature 555:210–215CrossRefPubMed
138.
Shin N-R, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS, Bae JW (2014) An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63:727–735CrossRefPubMed
139.
140.
Jackson MA, Verdi S, Maxan ME, Shin CM, Zierer J, Bowyer RCE, Martin T, Williams FMK, Menni C, Bell JT, Spector TD, Steves CJ (2018) Gut microbiota associations with common diseases and prescription medications in a population-based cohort. Nat Commun 9:2655CrossRefPubMedPubMedCentral
141.
Vesper B, Jawdi A, Altman K, Haines III G, Tao L, Radosevich J (2009) The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab 10:84–89CrossRefPubMed
142.
Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, Tigchelaar EF, Jankipersadsing SA, Cenit MC, Harmsen HJM, Dijkstra G, Franke L, Xavier RJ, Jonkers D, Wijmenga C, Weersma RK, Zhernakova A (2016) Proton pump inhibitors affect the gut microbiome. Gut 65:740–748CrossRefPubMed
143.
Ward EK, Schuster DP, Stowers KH, Royse AK, Ir D, Robertson CE, Frank DN, Austin GL (2014) The effect of PPI use on human gut microbiota and weight loss in patients undergoing laparoscopic Roux-en-Y gastric bypass. Obes Surg 24:1567–1571CrossRefPubMed
144.
Plovier H, Everard A, Druart C, Depommier C, van Hul M, Geurts L, Chilloux J, Ottman N, Duparc T, Lichtenstein L, Myridakis A, Delzenne NM, Klievink J, Bhattacharjee A, van der Ark KCH, Aalvink S, Martinez LO, Dumas ME, Maiter D, Loumaye A, Hermans MP, Thissen JP, Belzer C, de Vos WM, Cani PD (2016) A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med 23:107–113. https://​doi.​org/​10.​1038/​nm.​4236 CrossRefPubMed
145.
146.
de la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, Velásquez-Mejía EP, Carmona JA, Abad JM, Escobar JS (2017) Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid–producing microbiota in the gut. Diabetes Care 40:54–62CrossRefPubMed
147.
148.
149.
Arora T, Seyfried F, Docherty NG, Tremaroli V, le Roux CW, Perkins R, Bäckhed F (2017) Diabetes-associated microbiota in fa/fa rats is modified by Roux-en-Y gastric bypass. ISME J 11:2035–2046CrossRefPubMedPubMedCentral
150.
Casselbrant A, Elias E, Fändriks L, Wallenius V (2015) Expression of tight-junction proteins in human proximal small intestinal mucosa before and after Roux-en-Y gastric bypass surgery. Surg Obes Relat Dis 11:45–53CrossRefPubMed
151.
Monte SV, Caruana JA, Ghanim H, Sia CL, Korzeniewski K, Schentag JJ, Dandona P (2012) Reduction in endotoxemia, oxidative and inflammatory stress, and insulin resistance after Roux-en-Y gastric bypass surgery in patients with morbid obesity and type 2 diabetes mellitus. Surgery 151:587–593CrossRefPubMed
152.
Yang P-J, Lee WJ, Tseng PH, Lee PH, Lin MT, Yang WS (2014) Bariatric surgery decreased the serum level of an endotoxin-associated marker: lipopolysaccharide-binding protein. Surg Obes Relat Dis 10:1182–1187CrossRefPubMed
153.
Trøseid M et al (2013) Plasma lipopolysaccharide is closely associated with glycemic control and abdominal obesity: evidence from bariatric surgery. Diabetes Care 36:3627–3632CrossRefPubMedPubMedCentral
154.
Clemente-Postigo M, Roca-Rodriguez MM, Camargo A, Ocaña-Wilhelmi L, Cardona F, Tinahones FJ (2014) Lipopolysaccharide and lipopolysaccharide-binding protein levels and their relationship to early metabolic improvement after bariatric surgery. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 11:933–939. https://​doi.​org/​10.​1016/​j.​soard.​2014.​11.​030 CrossRef
155.
156.
le Roux CW, Bueter M, Theis N, Werling M, Ashrafian H, Löwenstein C, Athanasiou T, Bloom SR, Spector AC, Olbers T, Lutz TA (2011) Gastric bypass reduces fat intake and preference. Am J Physiol-Regul Integr Comp Physiol 301:R1057–R1066CrossRefPubMedPubMedCentral
157.
Kuribayashi H, Miyata M, Yamakawa H, Yoshinari K, Yamazoe Y (2012) Enterobacteria-mediated deconjugation of taurocholic acid enhances ileal farnesoid X receptor signaling. Eur J Pharmacol 697:132–138CrossRefPubMed
158.
Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y, Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Xu R, Wang M, Feng Q, Gong M, Yu J, Zhang Y, Zhang M, Hansen T, Sanchez G, Raes J, Falony G, Okuda S, Almeida M, LeChatelier E, Renault P, Pons N, Batto JM, Zhang Z, Chen H, Yang R, Zheng W, Li S, Yang H, Wang J, Ehrlich SD, Nielsen R, Pedersen O, Kristiansen K, Wang J (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490:55–60CrossRefPubMed
159.
Torres-Leal FL, Fonseca-Alaniz MH, Teodoro GFR, de Capitani MD, Vianna D, Pantaleão LC, Matos-Neto EM, Rogero MM, Donato J, Tirapegui J (2011) Leucine supplementation improves adiponectin and total cholesterol concentrations despite the lack of changes in adiposity or glucose homeostasis in rats previously exposed to a high-fat diet. Nutr Metab 8:62CrossRef
160.
161.
Binder E, Bermúdez-Silva FJ, Elie M, Leste-Lasserre T, Belluomo I, Clark S, Duchampt A, Mithieux G, Cota D (2014) Leucine supplementation modulates fuel substrates utilization and glucose metabolism in previously obese mice. Obes Silver Spring Md 22:713–720CrossRef
162.
Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy WS Jr, Eisenson H, Musante G, Surwit RS, Millington DS, Butler MD, Svetkey LP (2009) A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 9:311–326CrossRefPubMedPubMedCentral
163.
Pedersen HK, Gudmundsdottir V, Nielsen HB, Hyotylainen T, Nielsen T, Jensen BAH, Forslund K, Hildebrand F, Prifti E, Falony G, le Chatelier E, Levenez F, Doré J, Mattila I, Plichta DR, Pöhö P, Hellgren LI, Arumugam M, Sunagawa S, Vieira-Silva S, Jørgensen T, Holm JB, Trošt K, Consortium MHIT, Kristiansen K, Brix S, Raes J, Wang J, Hansen T, Bork P, Brunak S, Oresic M, Ehrlich SD, Pedersen O (2016) Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 535:376–381CrossRefPubMed
164.
Stancáková A et al (2012) Hyperglycemia and a common variant of GCKR are associated with the levels of eight amino acids in 9,369 Finnish men. Diabetes 61:1895–1902CrossRefPubMedPubMedCentral
165.
Cheng S, Rhee EP, Larson MG, Lewis GD, McCabe EL, Shen D, Palma MJ, Roberts LD, Dejam A, Souza AL, Deik AA, Magnusson M, Fox CS, O'Donnell CJ, Vasan RS, Melander O, Clish CB, Gerszten RE, Wang TJ (2012) Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation 125:2222–2231CrossRefPubMedPubMedCentral
166.
Lanza IR, Zhang S, Ward LE, Karakelides H, Raftery D, Nair KS (2010) Quantitative metabolomics by 1H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes. PLoS One 5:e10538CrossRefPubMedPubMedCentral
167.
Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE (2011) Metabolite profiles and the risk of developing diabetes. Nat Med 17:448–453CrossRefPubMedPubMedCentral
168.
Yoon M-S (2016) The emerging role of branched-chain amino acids in insulin resistance and metabolism. Nutrients 8
169.
170.
Morales NB & Plata CA. de. (2012) Role of AKT/mTORC1 pathway in pancreatic β-cell proliferation. Colomb Médica 43, 235–243–243
171.
Wei X, Yan X, Zou D, Yang Z, Wang X, Liu W, Wang S, Li X, Han J, Huang L, Yuan J (2013) Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach. BMC Gastroenterol 13:175CrossRefPubMedPubMedCentral
172.
Laferrère B et al (2011) Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci Transl Med 3:80re2–80re2CrossRefPubMedPubMedCentral
173.
Gralka E, Luchinat C, Tenori L, Ernst B, Thurnheer M, Schultes B (2015) Metabolomic fingerprint of severe obesity is dynamically affected by bariatric surgery in a procedure-dependent manner. Am J Clin Nutr 102:1313–1322CrossRefPubMed
174.
Lips MA, van Klinken JB, van Harmelen V, Dharuri HK, ’t Hoen PAC, Laros JFJ, van Ommen GJ, Janssen IM, van Ramshorst B, van Wagensveld BA, Swank DJ, van Dielen F, Dane A, Harms A, Vreeken R, Hankemeier T, Smit JWA, Pijl H, Willems van Dijk K (2014) Roux-en-Y gastric bypass surgery, but not calorie restriction, reduces plasma branched-chain amino acids in obese women independent of weight loss or the presence of type 2 diabetes. Diabetes Care 37:3150–3156CrossRefPubMed
175.
Lopes TIB, Geloneze B, Pareja JC, Calixto AR, Ferreira MMC, Marsaioli AJ (2016) “Omics” prospective monitoring of bariatric surgery: Roux-En-Y gastric bypass outcomes using mixed-meal tolerance test and time-resolved 1H NMR-based metabolomics. OMICS J Integr Biol 20:415–423CrossRef
176.
Magkos F, Bradley D, Schweitzer GG, Finck BN, Eagon JC, Ilkayeva O, Newgard CB, Klein S (2013) Effect of Roux-en-Y gastric bypass and laparoscopic adjustable gastric banding on branched-chain amino acid metabolism. Diabetes 62:2757–2761CrossRefPubMedPubMedCentral
177.
Narath SH, Mautner SI, Svehlikova E, Schultes B, Pieber TR, Sinner FM, Gander E, Libiseller G, Schimek MG, Sourij H, Magnes C (2016) An untargeted metabolomics approach to characterize short-term and long-term metabolic changes after bariatric surgery. PLoS One 11:e0161425CrossRefPubMedPubMedCentral
178.
Arora T, Velagapudi V, Pournaras DJ, Welbourn R, le Roux CW, Orešič M, Bäckhed F (2015) Roux-en-Y gastric bypass surgery induces early plasma metabolomic and lipidomic alterations in humans associated with diabetes remission. PLoS One 10:e0126401CrossRefPubMedPubMedCentral
179.
180.
Walford GA, Davis J, Warner AS, Ackerman RJ, Billings LK, Chamarthi B, Fanelli RR, Hernandez AM, Huang C, Khan SQ, Littleton KR, Lo J, McCarthy RM, Rhee EP, Deik A, Stolerman E, Taylor A, Hudson MS, Wang TJ, Altshuler D, Grant RW, Clish CB, Gerszten RE, Florez JC (2013) Branched chain and aromatic amino acids change acutely following two medical therapies for type 2 diabetes mellitus. Metabolism 62:1772–1778CrossRefPubMed
181.
Cotillard A, Poitou C, Torcivia A, Bouillot JL, Dietrich A, Klöting N, Grégoire C, Lolmede K, Blüher M, Clément K (2014) Adipocyte size threshold matters: link with risk of type 2 diabetes and improved insulin resistance after gastric bypass. J Clin Endocrinol Metab 99:E1466–E1470CrossRefPubMed
182.
Dalmas E, Rouault C, Abdennour M, Rovere C, Rizkalla S, Bar-Hen A, Nahon JL, Bouillot JL, Guerre-Millo M, Clément K, Poitou C (2011) Variations in circulating inflammatory factors are related to changes in calorie and carbohydrate intakes early in the course of surgery-induced weight reduction. Am J Clin Nutr 94:450–458CrossRefPubMed
183.
Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, Coupaye M, Pelloux V, Hugol D, Bouillot JL, Bouloumie A, Barbatelli G, Cinti S, Svensson PA, Barsh GS, Zucker JD, Basdevant A, Langin D, Clement K (2005) Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 54:2277–2286CrossRefPubMed
184.
Liu Y, Aron-Wisnewsky J, Marcelin G, Genser L, le Naour G, Torcivia A, Bauvois B, Bouchet S, Pelloux V, Sasso M, Miette V, Tordjman J, Clément K (2016) Accumulation and changes in composition of collagens in subcutaneous adipose tissue after bariatric surgery. J Clin Endocrinol Metab 101:293–304CrossRefPubMed
185.
García-Rubio J, León J, Redruello-Romero A, Pavón E, Cozar A, Tamayo F, Caba-Molina M, Salmerón J, Carazo Á (2018) Cytometric analysis of adipose tissue reveals increments of adipocyte progenitor cells after weight loss induced by bariatric surgery. Sci Rep 8:15203CrossRefPubMedPubMedCentral
186.
Faria G, Pestana D, Aral M, Preto J, Norberto S, Calhau C, Guimarães JT, Taveira-Gomes A (2014) Metabolic score: insights on the development and prediction of remission of metabolic syndrome after gastric bypass. Ann Surg 260:279–286CrossRefPubMed
187.
188.
Poitou C, Dalmas E, Renovato M, Benhamo V, Hajduch F, Abdennour M, Kahn JF, Veyrie N, Rizkalla S, Fridman WH, Sautès-Fridman C, Clément K, Cremer I (2011) CD14dimCD16+ and CD14+CD16+ monocytes in obesity and during weight loss: relationships with fat mass and subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 31:2322–2330CrossRefPubMed
189.
Rogacev KS, Ulrich C, Blomer L, Hornof F, Oster K, Ziegelin M, Cremers B, Grenner Y, Geisel J, Schlitt A, Kohler H, Fliser D, Girndt M, Heine GH (2010) Monocyte heterogeneity in obesity and subclinical atherosclerosis. Eur Heart J 31:369–376CrossRefPubMed
190.
Pecht T, Haim Y, Bashan N, Shapiro H, Harman-Boehm I, Kirshtein B, Clément K, Shai I, Rudich A (2016) Circulating blood monocyte subclasses and lipid-laden adipose tissue macrophages in human obesity. PLoS One 11:e0159350CrossRefPubMedPubMedCentral
191.
Chen H et al. Change in gut microbiota is correlated with alterations in the surface molecule expression of monocytes after Roux-en-Y gastric bypass surgery in obese type 2 diabetic patients. 12
192.
Viardot A, Lord RV, Samaras K (2010) The effects of weight loss and gastric banding on the innate and adaptive immune system in type 2 diabetes and prediabetes. J Clin Endocrinol Metab 95:2845–2850CrossRefPubMed
193.
Samaras K, Viardot A, Botelho NK, Jenkins A, Lord RV (2013) Immune cell-mediated inflammation and the early improvements in glucose metabolism after gastric banding surgery. Diabetologia 56:2564–2572CrossRefPubMed
194.
Magalhaes I, Pingris K, Poitou C, Bessoles S, Venteclef N, Kiaf B, Beaudoin L, da Silva J, Allatif O, Rossjohn J, Kjer-Nielsen L, McCluskey J, Ledoux S, Genser L, Torcivia A, Soudais C, Lantz O, Boitard C, Aron-Wisnewsky J, Larger E, Clément K, Lehuen A (2015) Mucosal-associated invariant T cell alterations in obese and type 2 diabetic patients. J Clin Invest 125:1752–1762CrossRefPubMedPubMedCentral
195.
196.
Tastan C, Karhan E, Zhou W, Fleming E, Voigt AY, Yao X, Wang L, Horne M, Placek L, Kozhaya L, Oh J, Unutmaz D (2018) Tuning of human MAIT cell activation by commensal bacteria species and MR1-dependent T-cell presentation. Mucosal Immunol 11:1591–1605CrossRefPubMedPubMedCentral
Metadata
Title
Impact of bariatric surgery on type 2 diabetes: contribution of inflammation and gut microbiome?
Authors
Jean Debédat
Chloé Amouyal
Judith Aron-Wisnewsky
Karine Clément
Publication date
01-07-2019
Publisher
Springer Berlin Heidelberg
Published in
Seminars in Immunopathology / Issue 4/2019
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-019-00738-3

Other articles of this Issue 4/2019

Seminars in Immunopathology 4/2019 Go to the issue

Review

Islet inflammation in type 2 diabetes

Review

Treatment of type 2 diabetes by targeting interleukin-1: a meta-analysis of 2921 patients

Review

Subclinical inflammation and depressive symptoms in patients with type 1 and type 2 diabetes

Review

Role of innate immune cells in metabolism: from physiology to type 2 diabetes

Review

The role of interleukin-6 in glucose homeostasis and lipid metabolism

Introduction

Inflammation and type 2 diabetes: from basic science to treatment
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits